Phosphonate prodrugs: an overview and recent advances

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17(8), 559–587 (2018). •• Prodrugs exist for a variety of functional groups and this article explains in great detail the importance of prodrugs and their expanding role in drug development.
  Medline CASGoogle Scholar
• 2. Albert A. Chemical aspects of selective toxicity. Nature, 182, 421–422 (1958).
  Medline CASGoogle Scholar
• 3. Wu K. A new classification of prodrugs: regulatory perspectives. Pharmaceuticals 2, 77–81 (2009).
  Medline CASGoogle Scholar
• 4. Buxton I, Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination in Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. Brunton L, Hilal-Dandan RKnollman B (Eds). McGraw-Hill, NY, USA (2018).
  Google Scholar
• 5. Goldstein AAronow LKalman S (Eds). Chapter 13: Drug Development in Principles of Drug Action. John Wiley & Sons, NJ, USA (1974).
  Google Scholar
• 6. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
  MedlineGoogle Scholar
• 7. Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. J. Med. Chem. 51(8), 2328–2345 (2008).
  Medline CASGoogle Scholar
• 8. Engel R. Phosphonates as analogues of natural phosphates. Chem. Rev. 77, 349–367 (1977).
  CASGoogle Scholar
• 9. Wiemer AJ, Wiemer DF. Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Top. Curr. Chem., 360, 115–160 (2015). • Wiemer and Wiemer excellently review not only the history and recent advances within phosphonate and phosphate prodrugs, but also include a thorough description of factors to consider when choosing a pro-moiety and how the active compound would be released.
  Medline CASGoogle Scholar
• 10. Kornberg RD, McNamee MG, McConnell HM. Measurement of transmembrane potentials in phospholipid vesicles. Proc. Natl Acad. Sci. USA, 69(6), 1508–1513 (1972).
  Medline CASGoogle Scholar
• 11. Wuts PGM (Ed.). Protection for the Phosphate Group in Greene's Protective Groups in Organic Synthesis. Wiley, NJ, USA (2014).
  Google Scholar
• 12. Niemi R, Turhanen P, Vepsalainen J, Taipale H, Jarvinen T. Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate. Eur. J. Pharm. Sci. 11(2), 173–180 (2000).
  Medline CASGoogle Scholar
• 13. Serafinowska HT, Ashton RJ, Bailey S, Harnden MR, Jackson SM, Sutton D. Synthesis and in vivo evaluation of prodrugs of 9-2-(phosphonomethoxy)ethoxy adenine. J. Med. Chem. 38(8), 1372–1379 (1995).
  Medline CASGoogle Scholar
• 14. Delombaert S, Erion MD, Tan J et al. N-phosphonomethyl dipeptides and their phosphonate prodrugs, a new-generation of neutral endopeptidase (NEP, EC-3.4.24.11) inhibitors. J. Med. Chem. 37(4), 498–511 (1994).
  Medline CASGoogle Scholar
• 15. Dang Q, Liu Y, Rydzewski RM et al. Bis (para-methoxy)benzyl phosphonate prodrugs with improved stability and enhanced cell penetration. Bioorg. Med. Chem. Lett. 17(12), 3412–3416 (2007).
  Medline CASGoogle Scholar
• 16. Christensen BG, Albers-Schonberg G, Leanza WJ. Antibiotic (-)-cis-(1,2-Epoxypropyl)phosphonates. DE1805682 Merck, Germany (1973).
  Google Scholar
• 17. Schultz C. Prodrugs of biologically active phosphate esters. Bioorg. Med. Chem. Lett. 11(6), 885–898 (2003).
  CASGoogle Scholar
• 18. Farquhar D, Srivastva DN, Kuttesch NJ, Saunders PP. Biologically reversible phosphate-protective groups. J. Pharm. Sci. 72(3), 324–325 (1983).
  Medline CASGoogle Scholar
• 19. Iyer RP, Phillips LR, Biddle JA et al. Synthesis of acyloxyanlkyl acylphosphonates as potential prodrugs of the antiviral, trisodium phosphonoformate (foscarnet sodium). Tet. Lett. 30(51), 7141–7144 (1989).
  CASGoogle Scholar
• 20. Marcellin P, Chang T, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New Eng. J. Med. 348(9), 808–816 (2003).
  Medline CASGoogle Scholar
• 21. Starrett JE, Tortolani DR, Russell J et al. Synthesis, oral bioavailability determination, and in-vitro evaluation of prodrugs of the antiviral agent 9-2-(phosphonomethoxy)ethyl adenine (PMEA). J. Med. Chem. 37(12), 1857–1864 (1994).
  Medline CASGoogle Scholar
• 22. Jackson ER, San Jose G, Brothers RC et al. The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs. Bioorg. Med. Chem. Lett. 24(2), 649–653 (2014).
  Medline CASGoogle Scholar
• 23. Bruecher K, Graewert T, Konzuch S et al. Prodrugs of reverse fosmidomycin analogues. J. Med. Chem. 58(4), 2025–2035 (2015).
  Medline CASGoogle Scholar
• 24. Faisca Phillips AM, Nogueira F, Murtinheira F, Barros MT. Synthesis and antimalarial evaluation of prodrugs of novel fosmidomycin analogues. Bioorg. Med. Chem. Lett. 25(10), 2112–2116 (2015).
  MedlineGoogle Scholar
• 25. Matsumoto K, Hayashi K, Murata-Hirai K et al. Targeting cancer cells with a bisphosphonate prodrug. Chemmedchem 11(24), 2656–2663 (2016).
  Medline CASGoogle Scholar
• 26. Kilcollins AM, Li J, Hsiao C-HC, Wiemer AJ. HMBPP analog prodrugs bypass energy-dependent uptake to promote efficient BTN3A1-mediated malignant cell lysis by V gamma 9 V delta 2 T lymphocyte effectors. J. Immunol. 197(2), 419–428 (2016).
  Medline CASGoogle Scholar
• 27. Shippy RR, Lin X, Agabiti SS et al. Phosphinophosphonates and their tris-pivaloyloxymethyl prodrugs reveal a negatively cooperative butyrophilin activation mechanism. J. Med. Chem. 60(6), 2373–2382 (2017).
  Medline CASGoogle Scholar
• 28. Tanaka Y, Iwasaki M, Murata-Hirai K et al. Anti-tumor activity and immunotherapeutic potential of a bisphosphonate prodrug. Sci. Rep. 7, (2017).
  Google Scholar
• 29. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol. Rev. 54(4), 589–598 (2002).
  Medline CASGoogle Scholar
• 30. The National Institute for Occupational Safety and Health Registry of Toxic Effects of Chemical Substances: pivalic acid. (2014). https://www.cdc.gov/niosh-rtecs/TO757E20.html
  Google Scholar
• 31. The National Institute for Occupational Safety and Health Registry of Toxic Effects of Chemical Substances: formaldehyde. https://www.cdc.gov/niosh-rtecs/LP882F48.html (2014)
  Google Scholar
• 32. Dhareshwar SS, Stella VJ. Your prodrug releases formaldehyde: should you be concerned? No! J. Pharm. Sci. 97(10), 4184–4193 (2008).
  Medline CASGoogle Scholar
• 33. Yuan LC, Dahl TC, Oliyai R. Degradation kinetics of oxycarbonyloxymethyl prodrugs of phosphonates in solution. Pharm. Res. 18(2), 234–237 (2001).
  Medline CASGoogle Scholar
• 34. Martin P, Lau DTY, Nguyen MH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 update. Clin. Gastroenterol. Hepatol. 13(12), 2071–2087 (2015).
  MedlineGoogle Scholar
• 35. Durand-Gasselin L, Van Rompay KKA, Vela JE et al. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol. Pharm. 6(4), 1145–1151 (2009).
  Medline CASGoogle Scholar
• 36. Lehman DA, Baeten JM, McCoy CO et al. Risk of drug resistance among persons acquiring hiv within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J. Infect. Dis. 211(8), 1211–1218 (2015).
  Medline CASGoogle Scholar
• 37. Keller MJ, Mesquita PM, Marzinke MA et al. A Phase I randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS 30(5), 743–751 (2016).
  Medline CASGoogle Scholar
• 38. Majer P, Jancarik A, Krecmerova M et al. Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA). J. Med. Chem. 59(6), 2810–2819 (2016).
  Medline CASGoogle Scholar
• 39. Perigaud C, Gosselin G, Lefebvre I et al. Rational design for cytosolic delivery of nucleoside monophosphate - SATE and DTE as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 3(12), 2521–2526 (1993).
  CASGoogle Scholar
• 40. Benzaria S, Pelicano H, Johnson R et al. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9- 2-(phosphonomethoxy)ethyl adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J. Med. Chem. 39(25), 4958–4965 (1996).
  Medline CASGoogle Scholar
• 41. Briggs AD, Camplo M, Freeman S, Lundstrom J, Pring BG. S-Acylthioethyl prodrugs of phosphonoformate. Eur. J. Pharm. Sci. 5(4), 199–208 (1997).
  CASGoogle Scholar
• 42. Oh CH, Liu LJ, Hong JH. Design and synthesis of dually branched 5'-norcarbocyclic adenosine phosphonodiester analogue as a new anti-HIV prodrug. Nucleosides Nucleotides Nucleic Acids 29(10), 721–733 (2010).
  Medline CASGoogle Scholar
• 43. Placidi L, De Meo M, Gosselin G et al. Evaluation of the mutagenic and genotoxic activities of anti-hepatitis B analogs of beta-L-adenosine by the Ames test and the Comet assay. Antivir. Res. 50(2), 139–145 (2001).
  Medline CASGoogle Scholar
• 44. Meier C, Gorbig U, Muller C, Balzarini J. cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach. J. Med. Chem. 48(25), 8079–8086 (2005).
  Medline CASGoogle Scholar
• 45. Meier C, Lorey M, De Clercq E, Balzarini J. cycloSal-2′, 3′-dideoxy-2′,3′-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. J. Med. Chem. 41(9), 1417–1427 (1998).
  Medline CASGoogle Scholar
• 46. Lebeau I, Andrei G, Dal Pozzo F et al. Activities of alkoxvalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob. Agents Chemother. 50(7), 2525–2529 (2006).
  Medline CASGoogle Scholar
• 47. Bischofberger N, Hitchcock MJM, Chen MS et al. 1-((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38(10), 2387–2391 (1994).
  Medline CASGoogle Scholar
• 48. Eriksson U, Peterson LW, Kashemirov BA et al. Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol. Pharm. 5(4), 598–609 (2008).
  Medline CASGoogle Scholar
• 49. Peterson LW, Sala-Rabanal M, Krylov IS, Serpi M, Kashemirov BA, McKenna CE. Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1. Mol. Pharm. 7(6), 2349–2361 (2010).
  Medline CASGoogle Scholar
• 50. Zalcharova VM, Serpi M, Krylov IS et al. Tyrosine-based 1-(S) 3-Hydroxy-2-(phosphonomethoxy)propyl cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. J. Med. Chem. 54(16), 5680–5693 (2011).
  MedlineGoogle Scholar
• 51. Keith KA, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother. 48(5), 1869–1871 (2004).
  Medline CASGoogle Scholar
• 52. Krecmerova M, Holy A, Andrei G et al. Synthesis of Ester Prodrugs of 9-(S)- 3-Hydroxy-2-(phosphonomethoxy)propyl -2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. J. Med. Chem. 53(19), 6825–6837 (2010).
  Medline CASGoogle Scholar
• 53. Erion MD, Reddy KR, Boyer SH et al. Design, synthesis, and characterization of a series of cytochrome P-450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126(16), 5154–5163 (2004).
  Medline CASGoogle Scholar
• 54. Reddy KR, Matelich MC, Ugarkar BG et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J. Med. Chem. 51(3), 666–676 (2008).
  Medline CASGoogle Scholar
• 55. Tillmann HL. Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr. Opin. Investig. Drugs. 8(8), 682–690 (2007).
  Medline CASGoogle Scholar
• 56. Ding Y, Zhang H, Li X et al. Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects. Hepatol. Int. 11(4), 390–400 (2017).
  MedlineGoogle Scholar
• 57. Erion MD, Cable EE, Ito BR et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc. Natl Acad. Sci. USA 104(39), 15490–15495 (2007).
  Medline CASGoogle Scholar
• 58. Boyer SH, Jiang H, Jacintho JD et al. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J. Med. Chem. 51(22), 7075–7093 (2008).
  Medline CASGoogle Scholar
• 59. Tsukada T, Tamaki K, Tanaka J et al. A prodrug approach towards the development of tricyclic-based FBPase inhibitors. Bioorg. Med. Chem. Lett. 20(9), 2938–2941 (2010).
  Medline CASGoogle Scholar
• 60. Hostetler KY, Aldern KA, Wan WB, Ciesla SL, Beadle JR. Alkoxyakl esters of (S)-9- 3-Hydroxy-2-(phosphonomethoxy)propyl adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 50(8), 2857–2859 (2006).
  Medline CASGoogle Scholar
• 61. Dal Pozzo F, Andrei G, Lebeau I et al. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antivir. Res. 75(1), 52–57 (2007).
  MedlineGoogle Scholar
• 62. Williams-Aziz SL, Hartline CB, Harden EA et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49(9), 3724–3733 (2005).
  Medline CASGoogle Scholar
• 63. Painter GR, Almond MR, Trost LC et al. Evaluation of hexadecyloxypropyl-9-R- 2-(phosphonomethoxy)propyl adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother. 51(10), 3505–3509 (2007).
  Medline CASGoogle Scholar
• 64. Lanier ER, Ptak RG, Lampert BM et al. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob. Agents Chemother. 54(7), 2901–2909 (2010).
  Medline CASGoogle Scholar
• 65. Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. New Eng. J. Med. 369(13), 1227–1236 (2013).
  Medline CASGoogle Scholar
• 66. Kern ER, Hartline C, Harden E et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46(4), 991–995 (2002).
  Medline CASGoogle Scholar
• 67. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl- 2-C-14 cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharm. 63(3), 678–681 (2003).
  CASGoogle Scholar
• 68. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318(2), 474–481 (2004).
  Medline CASGoogle Scholar
• 69. Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48(2), 404–412 (2004).
  Medline CASGoogle Scholar
• 70. Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Quenelle DC. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48(9), 3516–3522 (2004).
  Medline CASGoogle Scholar
• 71. Wan WB, Beadle JR, Hartline C et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 49(2), 656–662 (2005).
  Medline CASGoogle Scholar
• 72. Beadle JR, Hartline C, Aldern KA et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46(8), 2381–2386 (2002).
  Medline CASGoogle Scholar
• 73. Hostetler KY. Synthesis and early development of hexadecyloxypropyl-cidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2(10), 2213–2225 (2010).
  Medline CASGoogle Scholar
• 74. Florescu DF, Keck MA. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev. Anti Infect. Ther. 12(10), 1171–1178 (2014).
  Medline CASGoogle Scholar
• 75. Grimley MS, Chemaly RF, Englund JA et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled Phase II trial. Biol. Blood Marrow Transplant. 23(3), 512–521 (2017).
  Medline CASGoogle Scholar
• 76. Hiwarkar P, Amrolia P, Sivaprakasam P et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood 129(14), 2033–2037 (2017).
  Medline CASGoogle Scholar
• 77. Chimerix. The AdAPT trial; adenovirus after allogeneic pediatric transplantation. (2017). https://clinicaltrials.gov/ct2/show/NCT03339401
  Google Scholar
• 78. Giesler KE, Marengo J, Liotta DC. Reduction sensitive lipid conjugates of tenofovir: synthesis, stability, and antiviral activity. J. Med. Chem. 59(15), 7097–7110 (2016).
  Medline CASGoogle Scholar
• 79. Giesler KE, Liotta DC. Next-generation reduction sensitive lipid conjugates of tenofovir: antiviral activity and mechanism of release. J. Med. Chem. 59(22), 10244–10252 (2016).
  Medline CASGoogle Scholar
• 80. Devine KG, McGuigan C, Oconnor TJ, Nicholls SR, Kinchington D. Novel phosphate derivatives of zidovudine as anti-HIV compounds. AIDS 4(4), 371–373 (1990).
  Medline CASGoogle Scholar
• 81. Ray AS, Fordyce MW, Hitchcock MJM. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antivir. Res. 125, 63–70 (2016).
  Medline CASGoogle Scholar
• 82. Procházková E, Navrátil R, Janeba Z, Roithová J, Baszczyňski O. Reactive cyclic intermediates in the ProTide prodrugs activation: trapping the elusive pentavalent phosphorane. Org. Biomol. Chem. 17(2), 315–320 (2019).
  Medline CASGoogle Scholar
• 83. Erion MD, van Poelje PD, Dang Q et al. MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in Type 2 diabetes. Proc. Natl Acad. Sci. USA 102(22), 7970–7975 (2005).
  Medline CASGoogle Scholar
• 84. Dang Q, Kasibhatla SR, Jiang T et al. Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors. J. Med. Chem. 51(14), 4331–4339 (2008).
  Medline CASGoogle Scholar
• 85. van Poelje PD, Potter SC, Erion MD. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in Type 2 diabetes. Handb. Exp. Pharmacol. 203, 279–301 (2011).
  CASGoogle Scholar
• 86. Cesnek M, Jansa P, Smidkova M et al. Bisamidate prodrugs of 2-substituted 9- 2-(phosphonomethoxy)ethyl adenine (PMEA, adefovir) as selective inhibitors of adenylate cyclase toxin from bordetella pertussis. Chemmedchem 10(8), 1351–1364 (2015).
  Medline CASGoogle Scholar
• 87. Brehova P, Smidkova M, Skacel J et al. Design and synthesis of fluorescent acyclic nucleoside phosphonates as potent inhibitors of bacterial adenylate cyclases. Chemmedchem 11(22), 2534–2546 (2016).
  Medline CASGoogle Scholar
• 88. Smidkova M, Dvorakova A, Tloust'ova E, Cesnek M, Janeba Z, Mertlikova-Kaiserova H. Amidate prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine as inhibitors of adenylate cyclase toxin from Bordetella pertussis. Antimicrob. Agents Chemother. 58(2), 664–671 (2014).
  MedlineGoogle Scholar
• 89. Eng WS, Hockova D, Spacek P et al. First crystal structures of mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase: complexes with GMP and pyrophosphate and with acyclic nucleoside phosphonates whose prodrugs have antituberculosis activity. J. Med. Chem. 58(11), 4822–4838 (2015).
  Medline CASGoogle Scholar
• 90. Hockova D, Janeba Z, Naesens L et al. Antimalarial activity of prodrugs of N-branched acyclic nucleoside phosphonate inhibitors of 6-oxopurine phosphoribosyltransferases. Bioorg. Med. Chem. 23(17), 5502–5510 (2015).
  Medline CASGoogle Scholar
• 91. Spacek P, Keough DT, Chavchich M et al. Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs. Bioorg. Med. Chem. 25, 4008–4030 (2017).
  Medline CASGoogle Scholar
• 92. Spacek P, Keough DT, Chavchich M et al. Synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of plasmodium falciparum and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferase. J. Med. Chem. 60(17), 7539–7554 (2017).
  Medline CASGoogle Scholar
• 93. Ballatore C, McGuigan C, De Clercq E, Balzarini J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg. Med. Chem. Lett. 11(8), 1053–1056 (2001).
  Medline CASGoogle Scholar
• 94. Mehellou Y, Balzarini J, McGuigan C. Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. Chemmedchem 4(11), 1779–1791 (2009).
  Medline CASGoogle Scholar
• 95. Sofia MJ, Bao D, Chang W et al. Discovery of a beta-D-2′-Deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (psi-7977) for the treatment of hepatitis c virus. J. Med. Chem. 53(19), 7202–7218 (2010).
  Medline CASGoogle Scholar
• 96. Mackman RL, Ray AS, Hui HC et al. Discovery of GS-9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorg. Med. Chem. 18(10), 3606–3617 (2010).
  Medline CASGoogle Scholar
• 97. McGuigan C, Murziani P, Slusarczyk M et al. Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside. J. Med. Chem. 54(20), 7247–7258 (2011).
  Medline CASGoogle Scholar
• 98. Quintiliani M, Balzarini J, McGuigan C. Design, synthesis, and biological evaluation of C1-phosphonamidate analogues of 2-deoxy-D-ribose-l-phosphate. Tetrahedron 69(43), 9111–9119 (2013).
  CASGoogle Scholar
• 99. Pertusati F, Hinsinger K, Flynn AS et al. PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer. Eur. J. Med. Chem. 78, 259–268 (2014).
  Medline CASGoogle Scholar
• 100. McGuigan C, Derudas M, Gonczy B et al. ProTides of N-(3-(5-(2′-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. Bioorg. Med. Chem. 22(9), 2816–2824 (2014).
  Medline CASGoogle Scholar
• 101. Zano SP, Pate C, Frank M, Rock CO, Jackowski S. Correction of a genetic deficiency in pantothenate kinase 1 using phosphopantothenate replacement therapy. Mol. Gen. Metab. 116(4), 281–288 (2015).
  Medline CASGoogle Scholar
• 102. Liu C, Dumbre SG, Pannecouque C et al. Amidate prodrugs of deoxythreosyl nucleoside phosphonates as dual inhibitors of HIV and HBV replication. J. Med. Chem. 59(20), 9513–9531 (2016).
  Medline CASGoogle Scholar
• 103. James E, Pertusati F, Brancale A, McGuigan C. Kinase-independent phosphoramidate S1P(1) receptor agonist benzyl ether derivatives. Bioorg. Med. Chem. Lett. 27(6), 1371–1378 (2017).
  Medline CASGoogle Scholar
• 104. Luo M, Groaz E, Andrei G et al. Expanding the antiviral spectrum of 3-fluoro-2-(phosphonomethoxy)propyl acyclic nucleoside phosphonates: diamyl aspartate amidate prodrugs. J. Med. Chem. 60(14), 6220–6238 (2017).
  Medline CASGoogle Scholar
• 105. Osgerby L, Lai Y-C, Thornton PJ et al. Kinetin riboside and its ProTides activate the parkinson's disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization. J. Med. Chem. 60(8), 3518–3524 (2017).
  Medline CASGoogle Scholar
• 106. Pertusati F, Serpi M, McGuigan C. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antivir. Chem. Chemother. 22(5), 181–203 (2012).
  Medline CASGoogle Scholar
• 107. Pradere U, Garnier-Amblard EC, Coats SJ, Amblard F, Schinazi RF. Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem. Rev. 114(18), 9154–9218 (2014).
  Medline CASGoogle Scholar
• 108. Thornton PJ, Kadri H, Miccoli A, Mehellou Y. Nucleoside phosphate and phosphonate prodrug clinical candidates. J. Med. Chem. 59(23), 10400–10410 (2016).
  Medline CASGoogle Scholar
• 109. Mehellou Y. The ProTides boom. Chemmedchem 11(11), 1114–1116 (2016).
  Medline CASGoogle Scholar
• 110. Sinokrot H, Smerat T, Najjar A, Karaman R. Advanced prodrug strategies in nucleoside and non-nucleoside antiviral agents: a review of the recent five years. Molecules, 22(10), (2017).
  MedlineGoogle Scholar
• 111. Mehellou Y, Rattan HS, Balzarini J. The ProTide prodrug technology: from the concept to the clinic. J. Med. Chem. 61(6), 2211–2226 (2018). • Offers a fascinating look into the history of how ProTides came to be and how they have advanced since their inception.
  Medline CASGoogle Scholar
• 112. Slusarczyk M, Serpi M, Pertusati F. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antivir. Chem. Chemother. 26, (2018). •• Not only does the paper offer a brief introduction into the realm of antiviral nucleosides, but synthetic strategies to employ the ProTide method are discussed thoroughly.
  MedlineGoogle Scholar
• 113. Wang X, Dowd CS. The methylerythritol phosphate pathway: promising drug targets in the fight against tuberculosis. ACS Infect. Dis. 4(3), 278–290 (2018).
  Medline CASGoogle Scholar
• 114. Gershenzon J, Dudareva N. The function of terpene natural products in the natural world. Nat. Chem. Biol. 3(7), 408–414 (2007).
  Medline CASGoogle Scholar
• 115. Reichenberg A, Wiesner J, Weidemeyer C et al. Diaryl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Bioorg. Med. Chem. Lett. 11(6), 833–835 (2001).
  Medline CASGoogle Scholar
• 116. Ortmann R, Wiesner J, Reichenberg A et al. Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity. Bioorg. Med. Chem. Lett. 13(13), 2163–2166 (2003).
  Medline CASGoogle Scholar
• 117. Ortmann R, Wiesner J, Reichenberg A et al. Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Archiv. Der. Pharmazie. 338(7), 305–314 (2005).
  Medline CASGoogle Scholar
• 118. Kurz T, Schlueter K, Kaula U, Bergmann B, Walter RD, Geffken D. Synthesis and antimalarial activity of chain substituted pivaloyloxymethyl ester analogues of Fosmidomycin and FR900098. Bioorg. Med. Chem. 14(15), 5121–5135 (2006).
  Medline CASGoogle Scholar
• 119. Kurz T, Behrendt C, Kaula U, Bergmann B, Walter RD. alpha-phenylethyl substituted bis(pivaloyloxymethyl) ester analogues of fosmidomycin and FR900098. Aus. J. Chem. 60(3), 154–158 (2007).
  CASGoogle Scholar
• 120. Ponaire S, Zingle C, Tritsch D, Grosdemange-Billiard C, Rohmer M. Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents. Eur. J. Med. Chem. 51, 277–285 (2012).
  Medline CASGoogle Scholar
• 121. Jose GS, Jackson ER, Uh E et al. Design of potential bisubstrate inhibitors against Mycobacterium tuberculosis (Mtb) 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr)-evidence of a novel binding mode. Medchemcomm 4(7), 1099–1104 (2013).
  MedlineGoogle Scholar
• 122. San Jose G, Jackson ER, Haymond A et al. Structure-activity relationships of the MEPicides: N-acyl and O-linked analogs of fr900098 as inhibitors of Dxr from mycobacterium tuberculosis and yersinia pestis. ACS Infect. Dis. 2(12), 923–935 (2016).
  MedlineGoogle Scholar
• 123. Edwards RL, Brothers RC, Wang X et al. MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis. Sci.Rep. 7, (2017).
  Google Scholar
• 124. Wang X, Edwards RL, Bal H et al. MEPicides: alpha,beta-unsaturated fosmidomycin analogues as DXR inhibitors against malaria. J. Med. Chem. 61(19), 8847–8858 (2018).
  Medline CASGoogle Scholar
• 125. Uh E, Jackson ER, Jose GS et al. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg. Med. Chem. Lett. 21(23), 6973–6976 (2011).
  Medline CASGoogle Scholar
• 126. Wiemer AJ, Wiemer DF, Hohl RJ. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clin. Pharmacol. Ther. 90(6), 804–812 (2011).
  Medline CASGoogle Scholar
• 127. Monteil M, Migianu-Griffoni E, Sainte-Catherine O, Di Benedetto M, Lecouvey M. Bisphosphonate prodrugs: synthesis and biological evaluation in HuH7 hepatocarcinoma cells. Eur. J. Med. Chem. 77, 56–64 (2014).
  Medline CASGoogle Scholar
• 128. Troutman JM, Chehade KAH, Kiegiel K, Andres DA, Spielmann HP. Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate. Bioorg. Med. Chem. Lett. 14(19), 4979–4982 (2004).
  Medline CASGoogle Scholar
• 129. Zhang Y, Leon A, Song Y et al. Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines. J. Med. Chem. 49(19), 5804–5814 (2006).
  Medline CASGoogle Scholar
• 130. Wiemer AJ, Yu JS, Shull LW et al. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorg. Med. Chem. 16(7), 3652–3660 (2008).
  Medline CASGoogle Scholar
• 131. Foust BJ, Allen C, Holstein SA, Wiemer DF. A new motif for inhibitors of geranylgeranyl diphosphate synthase. Bioorg. Med. Chem. 24(16), 3734–3741 (2016).
  Medline CASGoogle Scholar
• 132. Tanaka Y, Murata-Hirai K, Iwasaki M et al. Expansion of human T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Sci. 109(3), 587–599 (2018).
  Medline CASGoogle Scholar
• 133. U.S. Food and Drug Administration approves Gilead's single tablet regimen genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) for treatment of HIV-1 infection (2015). http://www.gilead.com/news/press-releases/2015/11/us-food-and-drug-administration-approves-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv1-infection
  Google Scholar
• 134. Agarwal K, Fung SK, Nguyen TT et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J. Hepatol. 62(3), 533–540 (2015).
  Medline CASGoogle Scholar
• 135. Chan HLY, Fung S, Seto WK et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, Phase III, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1(3), 185–195 (2016).
  MedlineGoogle Scholar
• 136. Gallant JE, Daar ES, Raffi F et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled Phase III trial. Lancet HIV 3(4), E158–E165 (2016).
  MedlineGoogle Scholar
• 137. Sax PE, Wohl D, Yin MT et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase III, non-inferiority trials. Lancet 385(9987), 2606–2615 (2015).
  Medline CASGoogle Scholar
• 138. Orkin C, DeJesus E, Ramgopal M et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV 4(5), E195–E204 (2017).
  MedlineGoogle Scholar
• 139. Stray KM, Park Y, Babusis D et al. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. Antivir. Res., 140, 116–120 (2017).
  Medline CASGoogle Scholar
• 140. Naesens L, Balzarini J, Declercq E. Pharmacokinetics in mice of the antiretrovirals agent 9-(2-phosphonylmethoxyethyl)adenine. Drug Metab. Dispos. 20(5), 747–752 (1992).
  Medline CASGoogle Scholar
• 141. Liao S, Fan S-Y, Liu Q et al. In vitro evaluation of 9-(2-phosphonylmethoxyethyl)adenine ester analogues, a series of anti-HBV structures with improved plasma stability and liver release. Arch. Pharmacal Res. 37(11), 1416–1425 (2014).
  Medline CASGoogle Scholar
• 142. Liu C, Dumbre SG, Pannecouque C, Korba B, De Jonghe S, Herdewijn P. Synthesis and antiviral evaluation of base-modified deoxythreosyl nucleoside phosphonates. Org. Biomolec. Chem. 15(26), 5513–5528 (2017).
  Medline CASGoogle Scholar
• 143. Kaiser MM, Hockova D, Wang T-H et al. Synthesis and evaluation of novel acyclic nucleoside phosphonates as inhibitors of plasmodium falciparum and human 6-oxopurine phosphoribosyltransferases. Chemmedchem 10(10), 1707–1723 (2015).
  Medline CASGoogle Scholar
• 144. Kaiser MM, Baszczynski O, Hockova D et al. Acyclic nucleoside phosphonates containing 9-deazahypoxanthine and a five-membered heterocycle as selective inhibitors of plasmodial 6-oxopurine phosphoribosyltransferases. Chemmedchem 12(14), 1133–1141 (2017).
  Medline CASGoogle Scholar
• 145. Coen N, Duraffour S, Naesens L et al. Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon epstein-barr virus reactivation in P3HR-1 cells. J. Virol. 87(22), 12422–12432 (2013).
  Medline CASGoogle Scholar
• 146. Toth K, Spencer JF, Ying B et al. USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses. Antivir. Res. 153, 1–9 (2018).
  Medline CASGoogle Scholar